Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price gapped up before the market opened on Tuesday. The stock had previously closed at $388.5150, but opened at $439.05. Genmab A/S shares last traded at $439.05, with a volume of 68 shares changing hands.
Genmab A/S Stock Performance
The firm’s 50 day moving average is $350.66 and its two-hundred day moving average is $300.48. The stock has a market capitalization of $27.03 billion, a PE ratio of 34.44 and a beta of 0.75. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
- Off-Price, High-Yield: Why Ross Stores Is Defying the Retail Slump
- Whirlpool’s Stock Collapse Raises a Bigger Question About Its Recovery Potential
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
